| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activating HER2 mutations as emerging targets in multiple solid cancers
|
Connell, Claire M.
|
|
|
|
5 |
p.
|
artikel
|
| 2 |
Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis
|
Maiorano, B.A.
|
|
|
|
5 |
p.
|
artikel
|
| 3 |
A European survey on the insights of patients living with metastatic colorectal cancer: the patient journey before, during and after diagnosis - an Eastern European perspective
|
Maravic, Zorana
|
|
|
|
5 |
p.
|
artikel
|
| 4 |
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
|
Capoluongo, E.D.
|
|
|
|
5 |
p.
|
artikel
|
| 5 |
A novel clinical prognostic index for patients with advanced gastric cancer: possible contribution to the continuum of care
|
Shimozaki, K.
|
|
|
|
5 |
p.
|
artikel
|
| 6 |
A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer
|
Yang, X.
|
|
|
|
5 |
p.
|
artikel
|
| 7 |
A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer
|
Carlsson, G.
|
|
|
|
5 |
p.
|
artikel
|
| 8 |
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies
|
Paluch-Shimon, Shani
|
|
|
|
5 |
p.
|
artikel
|
| 9 |
A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck – the RESGEX study
|
Klinghammer, K.
|
|
|
|
5 |
p.
|
artikel
|
| 10 |
Are ERBB2 mutations a ‘ready for routine use’ target in patients with metastatic breast cancer?
|
Grinda, T.
|
|
|
|
5 |
p.
|
artikel
|
| 11 |
Artificial intelligence as an adjunct tool for breast oncologists – are we there yet?
|
Schlam, I.
|
|
|
|
5 |
p.
|
artikel
|
| 12 |
ASCO highlights podcast: head and neck cancers
|
Merlano, Marco
|
|
|
|
5 |
p.
|
artikel
|
| 13 |
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study
|
Lasagna, A.
|
|
|
|
5 |
p.
|
artikel
|
| 14 |
A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology
|
Al-Batran, S.-E.
|
|
|
|
5 |
p.
|
artikel
|
| 15 |
Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs
|
Chauca Strand, G.
|
|
|
|
5 |
p.
|
artikel
|
| 16 |
Association between post-operative hPG80 (circulating progastrin) detectable level and worse prognosis in glioblastoma
|
Doucet, L.
|
|
|
|
5 |
p.
|
artikel
|
| 17 |
Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis
|
Debaudringhien, M.
|
|
|
|
5 |
p.
|
artikel
|
| 18 |
Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
|
Tomita, Y.
|
|
|
|
5 |
p.
|
artikel
|
| 19 |
Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic
|
Baurain, Jean-François
|
|
|
|
5 |
p.
|
artikel
|
| 20 |
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer
|
Mountzios, G.
|
|
|
|
5 |
p.
|
artikel
|
| 21 |
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature
|
Viscardi, Giuseppe
|
|
|
|
5 |
p.
|
artikel
|
| 22 |
Aurora kinases in ovarian cancer
|
Pérez-Fidalgo, J. Alejandro
|
|
|
|
5 |
p.
|
artikel
|
| 23 |
Authors’ reply—Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does not
|
Zwart, W.H.
|
|
|
|
5 |
p.
|
artikel
|
| 24 |
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
|
de Wit, R.
|
|
|
|
5 |
p.
|
artikel
|
| 25 |
Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy
|
Nevala-Plagemann, Christopher
|
|
|
|
5 |
p.
|
artikel
|
| 26 |
Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology
|
Castelo-Branco, L.
|
|
|
|
5 |
p.
|
artikel
|
| 27 |
Biology of premature ageing in survivors of cancer
|
Cupit-Link, Margaret C.
|
|
|
|
5 |
p.
|
artikel
|
| 28 |
Breast cancer subtypes: implications for the treatment and survival of patients in Africa—a prospective cohort study from Mozambique
|
Brandão, Mariana
|
|
|
|
5 |
p.
|
artikel
|
| 29 |
B7x—from bench to bedside
|
Kaur, Gurbakhash
|
|
|
|
5 |
p.
|
artikel
|
| 30 |
Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States
|
Jain, P.
|
|
|
|
5 |
p.
|
artikel
|
| 31 |
Caring for the caregiver: a systematic review characterising the experience of caregivers of older adults with advanced cancers
|
Adashek, Jacob J.
|
|
|
|
5 |
p.
|
artikel
|
| 32 |
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
|
Preusser, Matthias
|
|
|
|
5 |
p.
|
artikel
|
| 33 |
Challenge of implementing clinical practice guidelines. Getting ESMO’s guidelines even closer to the bedside: introducing the ESMO Practising Oncologists’ checklists and knowledge and practice questions
|
Rauh, Stefan
|
|
|
|
5 |
p.
|
artikel
|
| 34 |
Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review
|
Garutti, M.
|
|
|
|
5 |
p.
|
artikel
|
| 35 |
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey
|
Orsi, G.
|
|
|
|
5 |
p.
|
artikel
|
| 36 |
Choosing wisely in oncology: necessity and obstacles
|
Saletti, Piercarlo
|
|
|
|
5 |
p.
|
artikel
|
| 37 |
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)
|
Ciardiello, D.
|
|
|
|
5 |
p.
|
artikel
|
| 38 |
Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change?
|
Lorusso, Domenica
|
|
|
|
5 |
p.
|
artikel
|
| 39 |
Comment on redefining authorship in the era of artificial intelligence: balancing ethics, transparency, and progress
|
Scimeca, M.
|
|
|
|
5 |
p.
|
artikel
|
| 40 |
Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types
|
Kulkarni, Amit A.
|
|
|
|
5 |
p.
|
artikel
|
| 41 |
Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer
|
Perakis, Samantha O.
|
|
|
|
5 |
p.
|
artikel
|
| 42 |
Correction
|
|
|
|
|
5 |
p.
|
artikel
|
| 43 |
Correction: Molecular profile of BRCA-mutated biliary tract cancers
|
|
|
|
|
5 |
p.
|
artikel
|
| 44 |
Correction: Oncological care organisation during COVID-19 outbreak
|
|
|
|
|
5 |
p.
|
artikel
|
| 45 |
Corrigendum to ‘Salivary gland cancer: ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up’
|
van Herpen, C.
|
|
|
|
5 |
p.
|
artikel
|
| 46 |
Critically ill patients with cancer: chances and limitations of intensive care medicine—a narrative review
|
Schellongowski, Peter
|
|
|
|
5 |
p.
|
artikel
|
| 47 |
CSCO joins ESMO Open—Cancer Horizons
|
Zielinski, Christoph C.
|
|
|
|
5 |
p.
|
artikel
|
| 48 |
CSF-1 and Ang-2 serum levels — prognostic and diagnostic partners in non-small cell lung cancer
|
Coelho, Ana Luísa
|
|
|
|
5 |
p.
|
artikel
|
| 49 |
Current highlights in lung cancer in 2021
|
Lim, K.H.J.
|
|
|
|
5 |
p.
|
artikel
|
| 50 |
Defining a role for systemic chemotherapy in local and advanced appendix adenocarcinoma ☆
|
Strach, M.C.
|
|
|
|
5 |
p.
|
artikel
|
| 51 |
Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer
|
Tarazona, Noelia
|
|
|
|
5 |
p.
|
artikel
|
| 52 |
Development, verification, and comparison of a risk stratification model integrating residual cancer burden to predict individual prognosis in early-stage breast cancer treated with neoadjuvant therapy
|
Hou, N.
|
|
|
|
5 |
p.
|
artikel
|
| 53 |
Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries
|
Soo, R.
|
|
|
|
5 |
p.
|
artikel
|
| 54 |
Dignity of Science and the use of ChatGPT as a co-author
|
Scimeca, M.
|
|
|
|
5 |
p.
|
artikel
|
| 55 |
Disparities of birth cohort effects on pancreatic cancer incidence between the United States and urban China
|
Yang, S.
|
|
|
|
5 |
p.
|
artikel
|
| 56 |
Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does not.
|
Socha, J.
|
|
|
|
5 |
p.
|
artikel
|
| 57 |
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
|
Del Re, M.
|
|
|
|
5 |
p.
|
artikel
|
| 58 |
Editorial Board
|
|
|
|
|
5 |
p.
|
artikel
|
| 59 |
Editorial Board
|
|
|
|
|
5 |
p.
|
artikel
|
| 60 |
Editorial Board
|
|
|
|
|
5 |
p.
|
artikel
|
| 61 |
Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial—EPOC 2 (JFMC49-1601-C5) ☆
|
Tanaka, Y.
|
|
|
|
5 |
p.
|
artikel
|
| 62 |
Effects of physical activity on depressive symptoms during breast cancer survivorship: a meta-analysis of randomised control trials
|
Patsou, Efrossini D.
|
|
|
|
5 |
p.
|
artikel
|
| 63 |
Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer: the ACCORE study
|
Lund, C.M.
|
|
|
|
5 |
p.
|
artikel
|
| 64 |
Emerging targets for anticancer vaccination: PD-1
|
Tobias, J.
|
|
|
|
5 |
p.
|
artikel
|
| 65 |
Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies
|
Ardini, Elena
|
|
|
|
5 |
p.
|
artikel
|
| 66 |
EPIC: an evaluation of the psychological impact of early-phase clinical trials in cancer patients
|
Jittla, P.
|
|
|
|
5 |
p.
|
artikel
|
| 67 |
Epigenetic biomarkers in cancer
|
Egger, Gerda
|
|
|
|
5 |
p.
|
artikel
|
| 68 |
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
|
Dittrich, Christian
|
|
|
|
5 |
p.
|
artikel
|
| 69 |
ESMO-Magnitude of Clinical Benefit Scale (MCBS) group
|
Amaral, Teresa
|
|
|
|
5 |
p.
|
artikel
|
| 70 |
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
|
Cherny, N.I.
|
|
|
|
5 |
p.
|
artikel
|
| 71 |
Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain
|
Roitberg, F.
|
|
|
|
5 |
p.
|
artikel
|
| 72 |
European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
|
Tzogani, Kyriaki
|
|
|
|
5 |
p.
|
artikel
|
| 73 |
Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity
|
Foster, Jared
|
|
|
|
5 |
p.
|
artikel
|
| 74 |
Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorectal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size
|
Sakamaki, Kentaro
|
|
|
|
5 |
p.
|
artikel
|
| 75 |
Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study
|
Garrone, Ornella
|
|
|
|
5 |
p.
|
artikel
|
| 76 |
Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer
|
Alsina, Maria
|
|
|
|
5 |
p.
|
artikel
|
| 77 |
Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy
|
Hassel, J.C.
|
|
|
|
5 |
p.
|
artikel
|
| 78 |
Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer
|
Wuerstlein, R.
|
|
|
|
5 |
p.
|
artikel
|
| 79 |
First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: a case study
|
Peccatori, Fedro Alessandro
|
|
|
|
5 |
p.
|
artikel
|
| 80 |
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
|
Reck, M.
|
|
|
|
5 |
p.
|
artikel
|
| 81 |
FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?
|
Lamarca, Angela
|
|
|
|
5 |
p.
|
artikel
|
| 82 |
From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
|
Pirker, Robert
|
|
|
|
5 |
p.
|
artikel
|
| 83 |
From N-of-one to series of exceptional responders: unlocking the mystery of outliers in oncology
|
Rodriguez, J.E.
|
|
|
|
5 |
p.
|
artikel
|
| 84 |
Gender representation on editorial boards of leading oncology journals
|
Dai, N.
|
|
|
|
5 |
p.
|
artikel
|
| 85 |
Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG)
|
Zarkavelis, George
|
|
|
|
5 |
p.
|
artikel
|
| 86 |
Genomic characterization of thymic epithelial tumors in a real-world dataset
|
Kurokawa, K.
|
|
|
|
5 |
p.
|
artikel
|
| 87 |
Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation
|
Heilig, Christoph E.
|
|
|
|
5 |
p.
|
artikel
|
| 88 |
Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment
|
Aamdal, E.
|
|
|
|
5 |
p.
|
artikel
|
| 89 |
High incidence of cetuximab-related infusion reactions in head and neck patients
|
Palomar Coloma, Virginia
|
|
|
|
5 |
p.
|
artikel
|
| 90 |
Highlights in breast cancer from ASCO 2016
|
Cardoso, Fatima
|
|
|
|
5 |
p.
|
artikel
|
| 91 |
How to read a next-generation sequencing report—what oncologists need to know
|
Schmid, S.
|
|
|
|
5 |
p.
|
artikel
|
| 92 |
How we treat HER2-positive brain metastases
|
Stavrou, E.
|
|
|
|
5 |
p.
|
artikel
|
| 93 |
Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment
|
Su, E.
|
|
|
|
5 |
p.
|
artikel
|
| 94 |
Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials
|
Filis, P.
|
|
|
|
5 |
p.
|
artikel
|
| 95 |
Immune checkpoint inhibitor administration during pregnancy: a case series
|
Andrikopoulou, A.
|
|
|
|
5 |
p.
|
artikel
|
| 96 |
Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study
|
Thiery-Vuillemin, Antoine
|
|
|
|
5 |
p.
|
artikel
|
| 97 |
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study
|
Raimondi, A.
|
|
|
|
5 |
p.
|
artikel
|
| 98 |
Impact of COVID-19 on anxiety levels among patients with cancer actively treated with systemic therapy
|
Sigorski, Dawid
|
|
|
|
5 |
p.
|
artikel
|
| 99 |
Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians
|
Chazan, G.
|
|
|
|
5 |
p.
|
artikel
|
| 100 |
Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis
|
de Azambuja, Evandro
|
|
|
|
5 |
p.
|
artikel
|
| 101 |
Implementation of lung cancer screening in Europe: challenges and potential solutions: summary of a multidisciplinary roundtable discussion
|
Field, John K.
|
|
|
|
5 |
p.
|
artikel
|
| 102 |
Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion
|
Baruchel, André
|
|
|
|
5 |
p.
|
artikel
|
| 103 |
Indicators of integration at ESMO Designated Centres of Integrated Oncology and Palliative Care
|
Hui, David
|
|
|
|
5 |
p.
|
artikel
|
| 104 |
Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer
|
Fasano, Morena
|
|
|
|
5 |
p.
|
artikel
|
| 105 |
Influenza in hospitalised patients with malignancy: a propensity score matching analysis
|
Li, Jiarui
|
|
|
|
5 |
p.
|
artikel
|
| 106 |
Innovative oncology products: time to revisit the strategy development?
|
Krendyukov, Andriy
|
|
|
|
5 |
p.
|
artikel
|
| 107 |
Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls
|
Horak, Peter
|
|
|
|
5 |
p.
|
artikel
|
| 108 |
Interventions to improve care coordination between primary healthcare and oncology care providers: a systematic review
|
Tomasone, Jennifer R.
|
|
|
|
5 |
p.
|
artikel
|
| 109 |
In the literature: August 2021
|
Gambardella, V.
|
|
|
|
5 |
p.
|
artikel
|
| 110 |
In the literature: October 2020
|
Gambardella, Valentina
|
|
|
|
5 |
p.
|
artikel
|
| 111 |
In the literature: October 2016
|
Cervantes, Andres
|
|
|
|
5 |
p.
|
artikel
|
| 112 |
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
|
Simonelli, M.
|
|
|
|
5 |
p.
|
artikel
|
| 113 |
I-SPY 2: optimising cancer drug development in the 21st century
|
Bartsch, Rupert
|
|
|
|
5 |
p.
|
artikel
|
| 114 |
Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?
|
Pirker, Robert
|
|
|
|
5 |
p.
|
artikel
|
| 115 |
KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy
|
Ambrogio, Chiara
|
|
|
|
5 |
p.
|
artikel
|
| 116 |
KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor
|
Serna-Blasco, R.
|
|
|
|
5 |
p.
|
artikel
|
| 117 |
Late decisions about treatment limitation in patients with cancer: empirical analysis of end-of-life practices in a haematology and oncology unit at a German university hospital
|
Mehlis, Katja
|
|
|
|
5 |
p.
|
artikel
|
| 118 |
Leptomeningeal metastasis from solid tumours: EANO–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
Le Rhun, E.
|
|
|
|
5 |
p.
|
artikel
|
| 119 |
Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1
|
Knapen, Daan Geert
|
|
|
|
5 |
p.
|
artikel
|
| 120 |
Letter re: Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study
|
Zhang, J.
|
|
|
|
5 |
p.
|
artikel
|
| 121 |
Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy
|
Hu, Y.-J.
|
|
|
|
5 |
p.
|
artikel
|
| 122 |
Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity
|
Yoo, Shin Hye
|
|
|
|
5 |
p.
|
artikel
|
| 123 |
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study
|
Boni, V.
|
|
|
|
5 |
p.
|
artikel
|
| 124 |
Macrophage repolarisation therapy in colorectal cancer
|
Halama, Niels
|
|
|
|
5 |
p.
|
artikel
|
| 125 |
Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis ☆
|
Gulia, S.
|
|
|
|
5 |
p.
|
artikel
|
| 126 |
Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion
|
Burke, Patrick W.
|
|
|
|
5 |
p.
|
artikel
|
| 127 |
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A
|
Catenacci, D.V.T.
|
|
|
|
5 |
p.
|
artikel
|
| 128 |
Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: implications for biopsy targeting, classification and therapy
|
Gempt, J.
|
|
|
|
5 |
p.
|
artikel
|
| 129 |
MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer
|
Petrelli, Annalisa
|
|
|
|
5 |
p.
|
artikel
|
| 130 |
MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF wt metastatic colorectal cancer ☆
|
Tabernero, J.
|
|
|
|
5 |
p.
|
artikel
|
| 131 |
Molecular findings reveal possible resistance mechanisms in a patient with ALK-rearranged lung cancer: a case report and literature review
|
Kougioumtzi, Anastasia
|
|
|
|
5 |
p.
|
artikel
|
| 132 |
Molecular pathology of cancer: how to communicate with disease
|
Birner, Peter
|
|
|
|
5 |
p.
|
artikel
|
| 133 |
Molecular target: pan-AKT in gastric cancer
|
Kang, Byung Woog
|
|
|
|
5 |
p.
|
artikel
|
| 134 |
Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer
|
Rolfo, Christian
|
|
|
|
5 |
p.
|
artikel
|
| 135 |
Multimodal survival prediction in advanced pancreatic cancer using machine learning
|
Keyl, J.
|
|
|
|
5 |
p.
|
artikel
|
| 136 |
Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review
|
Ulas, E.B.
|
|
|
|
5 |
p.
|
artikel
|
| 137 |
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era
|
Arpino, Grazia
|
|
|
|
5 |
p.
|
artikel
|
| 138 |
Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study
|
Planchard, D.
|
|
|
|
5 |
p.
|
artikel
|
| 139 |
Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer
|
Ou, Sai-Hong Ignatius
|
|
|
|
5 |
p.
|
artikel
|
| 140 |
Patient-reported outcomes in a phase II study of alectinib
|
Ohe, Yuichiro
|
|
|
|
5 |
p.
|
artikel
|
| 141 |
Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial
|
Kim, J.H.
|
|
|
|
5 |
p.
|
artikel
|
| 142 |
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
|
Sartore-Bianchi, Andrea
|
|
|
|
5 |
p.
|
artikel
|
| 143 |
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors ☆
|
Park, H.
|
|
|
|
5 |
p.
|
artikel
|
| 144 |
Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆
|
Gaspar, N.
|
|
|
|
5 |
p.
|
artikel
|
| 145 |
Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)
|
Bennouna, Jaafar
|
|
|
|
5 |
p.
|
artikel
|
| 146 |
Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial
|
Grassi, E.
|
|
|
|
5 |
p.
|
artikel
|
| 147 |
Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
|
Colon-Otero, Gerardo
|
|
|
|
5 |
p.
|
artikel
|
| 148 |
Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma
|
Dummer, Reinhard
|
|
|
|
5 |
p.
|
artikel
|
| 149 |
PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer
|
Pereira, Stephen P.
|
|
|
|
5 |
p.
|
artikel
|
| 150 |
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers
|
Dumbrava, E.E.
|
|
|
|
5 |
p.
|
artikel
|
| 151 |
Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)
|
Cho, E.H.
|
|
|
|
5 |
p.
|
artikel
|
| 152 |
Precision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision?
|
Aldea, M.
|
|
|
|
5 |
p.
|
artikel
|
| 153 |
Precision medicine’s new frontier: integrating palliative care at the right time
|
Sampetrean, A.
|
|
|
|
5 |
p.
|
artikel
|
| 154 |
Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study
|
Younger, E.
|
|
|
|
5 |
p.
|
artikel
|
| 155 |
Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases
|
Di Liso, Elisabetta
|
|
|
|
5 |
p.
|
artikel
|
| 156 |
Prognostic value of comorbidities in older patients with cancer: the ELCAPA cohort study
|
Benderra, M.-A.
|
|
|
|
5 |
p.
|
artikel
|
| 157 |
Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial
|
Van Cutsem, Eric
|
|
|
|
5 |
p.
|
artikel
|
| 158 |
QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer
|
Tabernero, Josep
|
|
|
|
5 |
p.
|
artikel
|
| 159 |
Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016
|
van Krieken, Han
|
|
|
|
5 |
p.
|
artikel
|
| 160 |
Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16
|
Yasui, H.
|
|
|
|
5 |
p.
|
artikel
|
| 161 |
Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy
|
Yoshino, Takayuki
|
|
|
|
5 |
p.
|
artikel
|
| 162 |
Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe
|
Hofman, P.
|
|
|
|
5 |
p.
|
artikel
|
| 163 |
Real-world features associated with cancer-related venous thromboembolic events
|
Peippo, Maija Helena
|
|
|
|
5 |
p.
|
artikel
|
| 164 |
Recurrent or primary metastatic cervical cancer: current and future treatments
|
Gennigens, C.
|
|
|
|
5 |
p.
|
artikel
|
| 165 |
Redefining authorship in the era of artificial intelligence: balancing ethics, transparency, and progress
|
Ergun, Y.
|
|
|
|
5 |
p.
|
artikel
|
| 166 |
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment
|
Peeters, M.
|
|
|
|
5 |
p.
|
artikel
|
| 167 |
Refining patient selection for breast cancer immunotherapy: beyond PD-L1
|
Kossai, M.
|
|
|
|
5 |
p.
|
artikel
|
| 168 |
Re: Safety and efficacy concerns of long-acting GnRH agonist trigger for ovulation induction in oncological patients undergoing oocyte cryopreservation: a call for caution and further investigation
|
Massarotti, C.
|
|
|
|
5 |
p.
|
artikel
|
| 169 |
Response to letter entitled: letter comments on: Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation
|
Gosney, J.R.
|
|
|
|
5 |
p.
|
artikel
|
| 170 |
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies
|
Hegde, Aparna
|
|
|
|
5 |
p.
|
artikel
|
| 171 |
Retrospective analysis of the prevalence of specialised palliative care services for patients with metastatic breast cancer
|
Jäger, Eva Maria
|
|
|
|
5 |
p.
|
artikel
|
| 172 |
Retrospective analysis of the prognostic implications of tumor spread through air spaces in lung adenocarcinoma patients treated with surgery
|
Gutierrez-Sainz, L.
|
|
|
|
5 |
p.
|
artikel
|
| 173 |
Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients
|
Kulkarni, A.A.
|
|
|
|
5 |
p.
|
artikel
|
| 174 |
Safety and efficacy concerns of long-acting GnRHa trigger for ovulation induction in oncological patients undergoing oocyte cryopreservation: a call for caution and further investigation
|
Ingold, C.
|
|
|
|
5 |
p.
|
artikel
|
| 175 |
Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature
|
Grob, Jean-Jacques
|
|
|
|
5 |
p.
|
artikel
|
| 176 |
SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic
|
Fuereder, Thorsten
|
|
|
|
5 |
p.
|
artikel
|
| 177 |
Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials
|
Conforti, F.
|
|
|
|
5 |
p.
|
artikel
|
| 178 |
Sex differences in cancer chemotherapy effects, and why we need to reconsider BSA-based dosing of chemotherapy
|
Wagner, Anna Dorothea
|
|
|
|
5 |
p.
|
artikel
|
| 179 |
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern
|
Lasagna, A.
|
|
|
|
5 |
p.
|
artikel
|
| 180 |
Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study
|
Dengina, Natalia
|
|
|
|
5 |
p.
|
artikel
|
| 181 |
Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies
|
Blay, J.-Y.
|
|
|
|
5 |
p.
|
artikel
|
| 182 |
Table of Contents
|
|
|
|
|
5 |
p.
|
artikel
|
| 183 |
Table of Contents
|
|
|
|
|
5 |
p.
|
artikel
|
| 184 |
Table of Contents
|
|
|
|
|
5 |
p.
|
artikel
|
| 185 |
Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations
|
Riudavets, M.
|
|
|
|
5 |
p.
|
artikel
|
| 186 |
Targeting immune checkpoints in breast cancer: an update of early results
|
Solinas, Cinzia
|
|
|
|
5 |
p.
|
artikel
|
| 187 |
Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study
|
Alanen, Virve
|
|
|
|
5 |
p.
|
artikel
|
| 188 |
The ‘Charter of Rights for Family Caregivers’. The role and importance of the caregiver: an Italian proposal
|
Antonella, Sisto
|
|
|
|
5 |
p.
|
artikel
|
| 189 |
The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box?
|
Ricci, Angela Dalia
|
|
|
|
5 |
p.
|
artikel
|
| 190 |
The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression
|
Kim, C.M.
|
|
|
|
5 |
p.
|
artikel
|
| 191 |
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
|
Kirchner, M.
|
|
|
|
5 |
p.
|
artikel
|
| 192 |
The paradigm shift to precision oncology between political will and cultural acceptance
|
Rassy, E.
|
|
|
|
5 |
p.
|
artikel
|
| 193 |
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
|
Troiani, Teresa
|
|
|
|
5 |
p.
|
artikel
|
| 194 |
The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report
|
Hardenberg, M.C.
|
|
|
|
5 |
p.
|
artikel
|
| 195 |
Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field
|
Marhold, Maximilian
|
|
|
|
5 |
p.
|
artikel
|
| 196 |
Tissue navigator, an important position in the Pathology laboratory in the Precision Medicine era
|
Tavora, F.
|
|
|
|
5 |
p.
|
artikel
|
| 197 |
Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study
|
Bordonaro, R.
|
|
|
|
5 |
p.
|
artikel
|
| 198 |
Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
|
Le Tourneau, C.
|
|
|
|
5 |
p.
|
artikel
|
| 199 |
Understanding EGFR heterogeneity in lung cancer
|
Passaro, Antonio
|
|
|
|
5 |
p.
|
artikel
|
| 200 |
UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO)
|
Vaz-Luis, Ines
|
|
|
|
5 |
p.
|
artikel
|
| 201 |
Unlocking digitally enabled research in oncology: the time is now
|
Franzoi, M.A.
|
|
|
|
5 |
p.
|
artikel
|
| 202 |
Unravelling the heterogeneity of soft tissue and bone sarcoma patients’ health-related quality of life: a systematic literature review with focus on tumour location
|
den Hollander, Dide
|
|
|
|
5 |
p.
|
artikel
|
| 203 |
What is new on the horizon in melanoma brain metastasis?
|
Margolin, Kim
|
|
|
|
5 |
p.
|
artikel
|
| 204 |
Worldwide cancer statistics of adolescents and young adults in 2019: a systematic analysis of the Global Burden of Disease Study 2019
|
You, L.
|
|
|
|
5 |
p.
|
artikel
|
| 205 |
Young oncologists’ perspective on the role and future of the clinician-scientist in oncology
|
Lim, K.H.J.
|
|
|
|
5 |
p.
|
artikel
|
Tijdschrift beschrijving